Flupentixol And Melitracen

# Flupentixol and Melitracen ## Overview - **Classification**: Fixed-dose combination of a low-potency antipsychotic (thioxanthene) and a tricyclic antidepressant. - **Mechanism**: Flupentixol acts as a dopamine receptor blocker. Melitracen is a tricyclic antidepressant-like compound, inhibiting reuptake of norepinephrine and serotonin. ## Primary Indications 1. **Anxiety** - Mild to moderate anxiety states. 2. **Depression** - Mild to moderate depressive states. 3. **Asthenia** - Conditions associated with lethargy or lack of energy. ## Adult Dosing ### Standard Dosing **Anxiety/Depression/Asthenia** - **Dose**: **0.5 mg flupentixol / 10 mg melitracen** (typically 1 tablet) - **Frequency**: **Twice daily (BID)**, in the morning and at midday. - **Route**: Oral - **Duration**: As directed by physician; often short-term initially. - **Maximum Dose**: **1 mg flupentixol / 20 mg melitracen BID** (2 tablets BID) in severe cases; total daily max **2 mg flupentixol / 40 mg melitracen**. ### Dose Adjustments - **Renal Impairment**: Use with caution. Consider reduced dose for severe impairment. No specific guidelines. - **Hepatic Impairment**: Use with caution, reduced dose may be needed. **Contraindicated in severe hepatic impairment.** - **Elderly Patients**: Start with lower doses (e.g., 1 tablet daily). Titrate slowly due to increased sensitivity to side effects. ## Pediatric Dosing ### Neonates (0-28 days) - **Not Recommended**: This combination is generally contraindicated in neonates due to lack of safety and efficacy data. ### Infants (1-12 months) - **Not Recommended**: This combination is generally contraindicated in infants due to lack of safety and efficacy data. ### Children (1-12 years) - **Not Recommended**: This combination is generally contraindicated in children due to lack of safety and efficacy data. ### Adolescents (13-18 years) - **Not Recommended**: This combination is generally contraindicated in adolescents due to lack of safety and efficacy data. ## Safety Information ### Contraindications - **Absolute**: Acute alcohol, barbiturate, or opioid intoxication. - **Absolute**: Comatose states. - **Absolute**: Severe cardiovascular disorders (e.g., recent MI, heart block). - **Absolute**: Severe hepatic or renal impairment. - **Absolute**: Untreated narrow-angle glaucoma, acute angle closure glaucoma. - **Absolute**: Concomitant use with MAOIs (or within 14 days of stopping MAOIs). - **Absolute**: Children and adolescents. - **Relative**: Pregnancy and lactation. ### Common Adverse Effects - **Very Common (>10%)**: Drowsiness, dry mouth. - **Common (1-10%)**: Dizziness, tremor, blurred vision, palpitations, constipation, nausea, increased sweating, fatigue, insomnia, headache. - **Serious but Rare**: Tachycardia, QT prolongation, arrhythmias, extrapyramidal symptoms (EPS), neuroleptic malignant syndrome (NMS), seizures, severe hepatic dysfunction, agranulocytosis. ### Key Drug Interactions - **MAOIs**: Risk of serotonin syndrome, hypertensive crisis. Avoid concurrent use and within 14 days. - **CNS Depressants (alcohol, benzodiazepines, opioids)**: Potentiated sedation, respiratory depression. Avoid or use with extreme caution. - **Anticholinergics (antihistamines, other TCAs)**: Increased risk of anticholinergic effects (dry mouth, urinary retention, blurred vision). - **Adrenergic drugs (epinephrine, norepinephrine)**: Potentiation of pressor effects. - **QT-prolonging drugs (some antiarrhythmics, antipsychotics, macrolides)**: Increased risk of QT prolongation and arrhythmias. - **Antihypertensives**: May potentiate hypotensive effects. ## Monitoring & Follow-up - **Before Treatment**: Baseline ECG (especially if cardiac risk factors), liver/renal function tests, ophthalmological exam (if glaucoma risk). - **During Treatment**: Monitor for cardiac symptoms, LFTs (if concerns), mental status changes, sedation, EPS symptoms. - **Clinical Signs**: Watch for worsening depression/anxiety, agitation, motor restlessness, urinary retention, constipation, vision changes, cardiac rhythm disturbances. ## Clinical Pearls - 💡 **Fixed-dose**: This is a fixed-dose combination; individual components cannot be dose-titrated separately. - 💡 **Onset of action**: Anxiolytic effect may be seen earlier, but antidepressant effect typically takes 2-4 weeks. - 💡 **Withdrawal**: Taper gradually if discontinuing after prolonged use to avoid withdrawal symptoms. - 💡 **Not for acute psychosis**: The low dose of flupentixol is not intended for acute psychotic episodes. - 💡 **Driving/Operating machinery**: Advise caution due to potential sedation and blurred vision. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.